3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Depression
4
Depressive Disorder, Major
2
Stomach Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Fatigue
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bile Duct Neoplasms
1
Asthma
1
Interventions
Cisplatin
75
Cetuximab
63
Radiotherapy
38
pembrolizumab
29
Radiotherapy, Intensity-Modulated
28
Carboplatin
25
Fluorouracil
24
Docetaxel
24
Paclitaxel
19
Erlotinib Hydrochloride
13
Nivolumab
12
Radiation
10
Pemetrexed
10
durvalumab
8
Gemcitabine
8
Drug Therapy
8
Bevacizumab
7
zalutumumab
6
Surgical Procedures, Operative
6
Panitumumab
6
Lapatinib
6
Everolimus
6
Albumin-Bound Paclitaxel
6
130-nm albumin-bound paclitaxel
6
epacadostat
5
Standard of Care
5
Oxaliplatin
5
Gefitinib
5
Afatinib
5
Radiosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Head and Neck Neoplasms
×
Escitalopram
×
Clear all
NCT00536172
2023-09-21
PROTECT
University of Nebraska
Phase 4
Completed
160 enrolled
15 charts